great work chelseadude65 !

First 70 Last

Share
Profile

Follow
Lefevre

9,779 Posts.

961

26/04/24

21:44

Post #: 73532596
Share

Originally posted by chelseadude65: ↑

I like to share a question i asked argenica about efficacy........they answered.................

dudemug65

You
07:17PM 20/03/2024
Whats the level of efficacy needed for arg 007 to be of interest to bigger buy in pharma companies ? and are the company confident it can acheive prior to listing on the asx ?

Hi Mark, Thanks for your question and we appreciate your support as a shareholder. It is worth noting that safety is the biggest hurdle to overcome when running clinical trials in neurological conditions in large unmet needs such as stroke. The regulatory bodies, including the FDA in the US, require that the drug does no harm to stroke patients for it to be approved. And then, given there are currently no neuroprotective drugs on the market, the efficacy hurdle is reasonably small, it just needs to be better than no treatment in terms of functional outcome.From our preclinical data in models that reflect the current standard of care, we showed a 66% reduction in brain tissue death after 24 hours and a 70% reduction 28 days after stroke, which resulted in an improvement to functional outcomes.The main aim of our current Phase 2 study is to prove that the drug is safe and does no harm to stroke patients, this will provide pharmaceutical companies comfort that the main hurdle for drug approval has been met. We will also be collecting a number of measures of efficacy which will hopefully point to the drug having an impact on reduction in brain cell death and functional outcomes for stroke patients, however it must be noted that the current Phase 2 study does not have enough people in it to provide a statistically significant functional outcome measure, but it will be able to tell us if there is a trend in efficacy. This, combined with the safety data, and all our previous preclinical data, should get the interest of phama companies who will then hopefully partner with Argenica to undertake a large Phase 3 study which will have enough patients to determine the functional outcome efficacy of ARG-007.

Thanks Argencia

Expand

great work chelseadude65 !

AGN Price at posting: 56.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

There are more pages in this discussion • 18 more messages in this thread...

First 70 Last

Add AGN (ASX) to my watchlist

(20min delay)
Last 80.0¢		Change 0.010(1.27%)		Mkt cap ! $92.15M

Open	High	Low	Value	Volume
79.0¢	80.0¢	74.0¢	$308.1K	402.4K

Buyers (Bids)

No.	Vol.	Price($)
1	60000	79.0¢

Sellers (Offers)

Price($)	Vol.	No.
80.0¢	1132	1

View Market Depth

No.	Vol.	Price($)
1	8868	0.765
1	38760	0.760
1	619	0.755
1	14810	0.750
4	25701	0.740

Price($)	Vol.	No.
0.795	3417	1
0.800	10000	1
0.810	55	1
0.845	1851	1
0.875	953	1

Last trade - 14.57pm 28/06/2024 (20 minute delay)

AGN (ASX) Chart

great work chelseadude65 !

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

great work chelseadude65 !

Top Stories

Recce's R327 found effective against E.coli during clinical trial

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News